Skip to main content

Table 1 Clinical features of study population at baseline and over the 4 months observation period

From: The challenges of gout flare reporting: mapping flares during a randomized controlled trial

Baseline
 Age, years, mean (SD) 56 (12)
 Male, n (%) 107 (89%)
 New Zealand European ethnicity, n (%) 74 (62%)
 New Zealand Māori ethnicity, n (%) 20 (17%)
 Pacific ethnicity, n (%) 16 (13%)
 Asian ethnicity, n (%) 10 (8%)
 Duration of gout, years, mean (SD) 15 (12)
 No. of self-reported flares in preceding 4 months, mean (SD) 4.5 (6.0)
 Allopurinol use, n (%) 64 (53%)
 Colchicine use, n (%) 32 (27%)
 Prednisone use, n (%) 16 (13%)
 NSAID use, n (%) 60 (50%)
 Presence of tophi, n (%) 43 (36%)
 Serum urate, mmol/L, mean (SD) 0.42 (0.10)
Observation period
 Days to first self-reported flare, mean (SD) 13.1 (27.6)
 Number of self-reported flares, mean (SD) 2.1 (2.0)
 Number of months with ≥1 self-reported flare, mean (SD) 2.4 (1.3)
 Days with self-reported flare, mean (SD) 21.1 (18.3)
 Days to first Gaffo-CART defined, mean (SD) 41.3 (47.3)
 Number of Gaffo-CART defined flares, mean (SD) 0.9 (1.0)
 Number of months with ≥1 Gaffo-CART defined flare, mean (SD) 1.7 (1.3)
 Days with Gaffo-CART defined flare, mean (SD) 7.9 (9.3)
 Average pain score (range 0–10), mean (SD) a 0.77 (1.74)
 Average swollen joint count (/66), mean (SD)b 0.66 (1.57)
 Average tender joint count (/68), mean (SD) b 0.67 (1.24)
 Average C-reactive protein, mg/L, mean (SD) b 4.59 (7.47
 Average physician global assessment (range 0–5), mean (SD) b 1.46 (1.23)
 Average patient global assessment (range 0–5), mean (SD) b 1.46 (1.24)
  1. ameasured daily over the 4 months observation period, b measured monthly over the 4 months observation period